Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
预测和预防非裔美国儿童化疗引起的心脏毒性
基本信息
- 批准号:10275329
- 负责人:
- 金额:$ 68.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-05 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAdolescentAdultAffectAfrican AmericanAgeAlgorithmsAmericanAnthracyclineAreaBiochemicalBiologicalBiological AssayBlastomaBody mass indexCRISPR/Cas technologyCancer PatientCandidate Disease GeneCardiac MyocytesCardiomyopathiesCardiotoxicityChestChildChromatinClinicalClinical DataClinical ResearchCommon Terminology Criteria for Adverse EventsComplicationCorrelation StudiesCoupledCryopreservationDataDetectionDoseDoxorubicinDrug PrescriptionsDrug usageEnhancersEtiologyEuropeanExposure toGene ExpressionGenesGeneticGenetic studyGenomeGenomicsGenotypeHeart TransplantationHeart failureHematologic NeoplasmsHigh PrevalenceHumanIn VitroIndividualKnowledgeLeadLinkage DisequilibriumMalignant Childhood NeoplasmMediatingMetabolismMethodologyModalityOncologistOnline SystemsParticipantPathway interactionsPatientsPerformancePharmaceutical PreparationsPhenotypePhysiologicalPredispositionProcessQuantitative Trait LociRARG geneRNA SplicingRadiation therapyRegulatory ElementResearchRiskRisk FactorsRoleRouteSaint Jude Children&aposs Research HospitalSamplingSingle Nucleotide PolymorphismSolidSurvivorsTimeTranslatingValidationVariantWorkalternative treatmentbasecancer diagnosiscardioprotectionchemotherapychildhood cancer survivorclinical applicationclinical riskcohortdifferential expressionepigenomeexperiencegenetic variantgenome editinggenome sequencinggenome wide association studygenomic toolshuman modelinduced pluripotent stem cellinnovationinterestleukemia/lymphomamembernovelpediatric patientspreventpromoterracial disparityresponserisk predictionrisk prediction modelsarcomasextooltranscriptometranscriptome sequencinguser-friendlywhole genome
项目摘要
Project Summary
Doxorubicin is a member of the anthracycline group of chemotherapy drugs prescribed to approximately 60% of
pediatric cancer patients suffering with sarcomas, blastomas, leukemia, and lymphoma. Although doxorubicin is
highly effective in these patients, ~16% of pediatric patients suffer doxorubicin-induced cardiotoxicity (DIC) which
can lead to heart failure requiring heart transplant. Our recent work has shown that DIC is 2.5x more
prevalent in African American (AA) survivors of childhood cancer. Despite more than 50 years of research
in this field, there is still, at present, little potential for either predicting or preventing DIC. There is an obvious
need for novel and innovative approaches to overcome this hurdle. Candidate gene and genome-wide
association studies, predominantly in Europeans, have identified >100 single nucleotide polymorphisms (SNPs)
that are statistically correlated with DIC, yet experimental validation has not been feasible due to the difficulty in
isolating and culturing human cardiomyocytes in vitro. In our recent work, we showed that patient-specific human
induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are efficient predictors of a patient’s
likelihood of developing DIC, confirming for the first time that there is a genomic basis to DIC. Here, we
hypothesize that hiPSC-CMs can be utilized in three different modalities to study genetic variants associated
with DIC in AA survivors: firstly, to discover novel predictive SNPs; secondly, to validate SNPs; and thirdly, to
examine the modulated pathways and determine genotype-specific cardioprotective methodologies. In Aim 1,
we will generate hiPSC from 100 AA adult survivors of childhood cancer with diverse biological covariates who
were exposed to doxorubicin assess their response to doxorubicin in vitro to validate our previous findings and
verify the power of this tool. In Aim 2, we will use these 100 patient-specific lines to identify drug response
differential expression, splicing and chromatin accessibility quantitative trait loci (deQTL, dsQTL and dcaQTL),
assessing biological covariates such as doxorubicin dose, age at cancer diagnosis, attained age, sex, BMI,
radiotherapy (other than involving chest), and cancer diagnosis both individually and combined. We will then
validate these variants with genome editing, and mechanistically examine pathways causative to DIC
susceptibility concentrating on genes with known roles in cardiomyopathy, cardioprotection, and doxorubicin
metabolism. We will then use the discoveries above to discover/repurpose genome-informed cardioprotective
drugs to prevent DIC in a genotype-specific manner. In Aim 3, we will build a risk prediction model for DIC among
AA survivors incorporating clinical risk factors and functionally assessed genetic variants above, evaluate its
prediction performance, validate it in independent AA survivors, and implement it in a web-based and user-
friendly tool for broader clinical and research use. In summary, this work will deliver us the genetic rationale for
why AA survivors experience DIC and provide 1, fully human validated SNP data for clinical application through
a user-friendly tool, and 2, novel cardioprotective pathways that can be targeted to protect against DIC.
项目摘要
阿霉素是蒽环类化疗药物中的一员,约有60%的
患有肉瘤、母细胞瘤、白血病和淋巴瘤的儿童癌症患者。虽然阿霉素是一种
在这些患者中非常有效的,约16%的儿科患者遭受阿霉素引起的心脏毒性(DIC),其中
会导致心力衰竭,需要进行心脏移植。我们最近的工作表明,DIC是原来的2.5倍
流行于儿童癌症的非裔美国人(AA)幸存者。尽管经过了50多年的研究
在这一领域,目前预测或预防DIC的潜力仍然很小。有一个明显的
需要新的和创新的方法来克服这一障碍。候选基因和全基因组
以欧洲人为主的协会研究已经确定了>;100单核苷酸多态(SNPs)。
在统计上与DIC相关,但由于以下困难,实验验证尚不可行
体外分离培养人心肌细胞。在我们最近的工作中,我们展示了特定于患者的人类
诱导多能干细胞来源的心肌细胞(hiPSC-CMS)是预测患者
DIC发生的可能性,首次证实DIC存在基因组基础。在这里,我们
假设HiPSC-CMS可以用三种不同的方式来研究相关的遗传变异
对再生障碍性贫血幸存者进行DIC:第一,发现新的预测性SNPs;第二,验证SNPs;第三,
检查调节的通路并确定特定的基因型别的心肌保护方法。在目标1中,
我们将从100名儿童癌症AA成年幸存者中产生HiPSC,这些幸存者具有不同的生物协变量
在体外评估他们对阿霉素的反应,以验证我们之前的发现和
验证此工具的威力。在目标2中,我们将使用这100条特定于患者的线路来识别药物反应
差异表达、剪接和染色质可及性数量性状基因座(deQTL、dsQTL和dcaQTL),
评估生物协变量,如阿霉素剂量、癌症诊断年龄、达到的年龄、性别、BMI、
放射治疗(胸部除外)和癌症诊断,包括单独诊断和合并诊断。到时候我们会的
通过基因组编辑验证这些变异,并机械地检查导致DIC的途径
易感性集中在已知在心肌病、心肌保护和阿霉素中起作用的基因
新陈代谢。然后,我们将使用上面的发现来发现/重新利用基因组信息的心脏保护
用于预防DIC的药物具有特定的基因型别。在目标3中,我们将建立DIC的风险预测模型
纳入临床风险因素和上述功能性评估基因变异的再生障碍性贫血幸存者,评估其
预测性能,在独立的AA幸存者中进行验证,并在基于Web的用户中实施-
友好的工具,用于更广泛的临床和研究用途。总而言之,这项工作将为我们提供
为什么再生障碍性贫血幸存者会经历DIC,并通过以下方式提供1个完全由人类验证的SNP数据供临床应用
一个用户友好的工具,和2,新的心脏保护途径,可以有针对性地防止DIC。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul W. Burridge其他文献
MorPhiC Consortium: towards functional characterization of all human genes
形态学联盟:致力于所有人类基因的功能表征
- DOI:
10.1038/s41586-024-08243-w - 发表时间:
2025-02-12 - 期刊:
- 影响因子:48.500
- 作者:
Mazhar Adli;Laralynne Przybyla;Tony Burdett;Paul W. Burridge;Pilar Cacheiro;Howard Y. Chang;Jesse M. Engreitz;Luke A. Gilbert;William J. Greenleaf;Li Hsu;Danwei Huangfu;Ling-Hong Hung;Anshul Kundaje;Sheng Li;Helen Parkinson;Xiaojie Qiu;Paul Robson;Stephan C. Schürer;Ali Shojaie;William C. Skarnes;Damian Smedley;Lorenz Studer;Wei Sun;Dušica Vidović;Thomas Vierbuchen;Brian S. White;Ka Yee Yeung;Feng Yue;Ting Zhou - 通讯作者:
Ting Zhou
Examining patient-specific responses to PARP inhibitors in a novel, human induced pluripotent stem cell-based model of breast cancer
在一种新颖的基于人类诱导多能干细胞的乳腺癌模型中检查患者对聚腺苷二磷酸核糖聚合酶抑制剂的特异性反应
- DOI:
10.1038/s41698-025-00837-5 - 发表时间:
2025-02-25 - 期刊:
- 影响因子:8.000
- 作者:
Carly J. Weddle;Malorie Blancard;Nnamdi Uche;Praeploy Pongpamorn;Romina B. Cejas;Paul W. Burridge - 通讯作者:
Paul W. Burridge
Serum Proteins Predict Treatment-Related Cardiomyopathy Among Survivors of Childhood Cancer
血清蛋白可预测儿童癌症幸存者中与治疗相关的心肌病
- DOI:
10.1016/j.jaccao.2024.10.004 - 发表时间:
2025-01-01 - 期刊:
- 影响因子:12.800
- 作者:
Suresh Poudel;Him Shrestha;Yue Pan;Qian Li;Kendrick Li;Cindy Im;Stephanie B. Dixon;Matthew J. Ehrhardt;Daniel A. Mulrooney;Suiping Zhou;Haiyan Tan;Anthony A. High;Paul W. Burridge;Smita Bhatia;John L. Jefferies;Kirsten K. Ness;Melissa M. Hudson;Leslie L. Robison;Gregory T. Armstrong;Junmin Peng;Yadav Sapkota - 通讯作者:
Yadav Sapkota
Paul W. Burridge的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul W. Burridge', 18)}}的其他基金
Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
预测和预防非裔美国儿童化疗引起的心脏毒性
- 批准号:
10462680 - 财政年份:2021
- 资助金额:
$ 68.45万 - 项目类别:
Predicting and Preventing Chemotherapy-Induced Cardiotoxicity in African American Children
预测和预防非裔美国儿童化疗引起的心脏毒性
- 批准号:
10675503 - 财政年份:2021
- 资助金额:
$ 68.45万 - 项目类别:
HiDef B8: Commercialization and scaled production of defined, robust, and cost-effective media for iPSCs
HiDef B8:用于 iPSC 的明确、稳健且经济高效的介质的商业化和规模化生产
- 批准号:
10405556 - 财政年份:2021
- 资助金额:
$ 68.45万 - 项目类别:
HiDef B8: Commercialization and scaled production of defined, robust, and cost-effective media for iPSCs
HiDef B8:用于 iPSC 的明确、稳健且经济高效的介质的商业化和规模化生产
- 批准号:
10255392 - 财政年份:2021
- 资助金额:
$ 68.45万 - 项目类别:
Genomic Prediction of Doxorubicin-Induced Cardiotoxicity
阿霉素引起的心脏毒性的基因组预测
- 批准号:
10456312 - 财政年份:2018
- 资助金额:
$ 68.45万 - 项目类别:
Genomic Prediction of Doxorubicin-Induced Cardiotoxicity
阿霉素引起的心脏毒性的基因组预测
- 批准号:
10524092 - 财政年份:2018
- 资助金额:
$ 68.45万 - 项目类别:
Genomic Prediction of Doxorubicin-Induced Cardiotoxicity
阿霉素引起的心脏毒性的基因组预测
- 批准号:
10228683 - 财政年份:2018
- 资助金额:
$ 68.45万 - 项目类别:
Assessing the ability of hiCMs to recapitulate patient-specific doxorubicin-induced cardiotoxicity
评估 hiCM 重现患者特异性阿霉素引起的心脏毒性的能力
- 批准号:
10274149 - 财政年份:2018
- 资助金额:
$ 68.45万 - 项目类别:
Modeling the role of the genome in chemotherapy induced cardiotoxicity using iPSC
使用 iPSC 模拟基因组在化疗引起的心脏毒性中的作用
- 批准号:
9330916 - 财政年份:2015
- 资助金额:
$ 68.45万 - 项目类别:
Modeling the role of the genome in chemotherapy induced cardiotoxicity using iPSC
使用 iPSC 模拟基因组在化疗引起的心脏毒性中的作用
- 批准号:
9130233 - 财政年份:2015
- 资助金额:
$ 68.45万 - 项目类别:
相似海外基金
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 68.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
- 批准号:
10755168 - 财政年份:2023
- 资助金额:
$ 68.45万 - 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
- 批准号:
480840 - 财政年份:2023
- 资助金额:
$ 68.45万 - 项目类别:
Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
- 批准号:
10678157 - 财政年份:2023
- 资助金额:
$ 68.45万 - 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
- 批准号:
10744412 - 财政年份:2023
- 资助金额:
$ 68.45万 - 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
- 批准号:
23K07305 - 财政年份:2023
- 资助金额:
$ 68.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
- 批准号:
23H02874 - 财政年份:2023
- 资助金额:
$ 68.45万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Effects of adolescent social isolation on adult decision making and corticostriatal circuitry
青少年社会隔离对成人决策和皮质纹状体回路的影响
- 批准号:
10756652 - 财政年份:2023
- 资助金额:
$ 68.45万 - 项目类别:
Adolescent trauma produces enduring disruptions in sleep architecture that lead to increased risk for adult mental illness
青少年创伤会对睡眠结构产生持久的破坏,从而导致成人精神疾病的风险增加
- 批准号:
10730872 - 财政年份:2023
- 资助金额:
$ 68.45万 - 项目类别:
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
- 批准号:
10650648 - 财政年份:2023
- 资助金额:
$ 68.45万 - 项目类别: